Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - May 14, 2008) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ), today
announced that the Company is scheduled to present at the Rodman & Renshaw
5th Annual Global Healthcare Conference, on May 19-20, in Monte Carlo.
Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland
BioLabs, will give a presentation followed by a question and answer session
on May 19, at 10:00 a.m. Central European Summer Time. The presentation
webcast may be accessed at the Company's website, www.cbiolabs.com under
investor information, or at http://www.wsw.com/webcast/rrshq13/cbli.
A replay of the presentation will be archived for 90 days after the
conference at the same locations. For more information about the Rodman &
Renshaw 5th Annual Global Healthcare Conference, please visit Rodman &
Renshaw's website at www.rodmanandrenshaw.com.
Cleveland BioLabs is developing a pipeline of products from two primary
families of compounds: Protectans and Curaxins. Protectans are being
developed as drug candidates that protect normal tissues from acute
stresses such as radiation and chemotherapy. Curaxins are being developed
as anticancer agents that could act as mono-therapy drugs or in combination
with other existing anticancer agents.
The Company recently announced completion of enrollment for its ongoing
Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory
(androgen independent) prostate cancer. CBLC102 is an orally administered,
small molecule designed to kill tumor cells through multiple mechanisms of
action targeting signaling pathways frequently deregulated in cancer.
The Company received a contract from the Department of Defense valued at up
to $8.9 million for the advanced development of Protectan CBLB502 as a
medical radiation countermeasure to treat radiation injury following
exposure to radiation from nuclear or radiological weapons. Protectan
CBLB502 is undergoing expedited approval for biodefense use through the
FDA's two-animal rule requiring efficacy in animals and safety testing in a
representative sample of healthy human volunteers. Protectan CBLB502 has
demonstrated animal efficacy and is expected to start human safety studies
in 2008. A Phase I/II medical trial for Protectan CBLB502 in head and neck
cancer patients for reduction of radiation and chemotherapy toxicities is
also expected to start later in 2008.
Science Magazine published a breakthrough peer-reviewed paper on Protectan
CBLB502's radioprotective capabilities in the April 11, 2008 issue. The
paper demonstrated the success of Cleveland BioLabs's principle proprietary
approach to protection of healthy tissue from a variety of potentially
lethal cellular stresses and underscored Protectan CBLB502's potential as a
radioprotector in both defense and medical settings.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland
Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland
BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's periodic filings with the
Securities and Exchange Commission.